Explaining the poor bacteriologic eradication rate of single-dose ceftriaxone in group A streptococcal tonsillopharyngitis: A reverse engineering solution using pharmacodynamic modeling

Pediatrics

Volumn 116, Issue 4, 2005, Pages 927-932

  Blumer, Jeffrey L ^a,d   Reed, Michael D ^a   Kaplan, Edward L ^b   Drusano, George L ^c  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c ORDWAY RESEARCH INSTITUTE   (United States)

^d TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Ceftriaxone; Pharmacodynamics; Pharmacokinetics; Pharyngitis; Tonsillopharyngitis

Indexed keywords

CEFTRIAXONE; ANTIINFECTIVE AGENT;

ARTICLE; BACTERICIDAL ACTIVITY; CHILD; CONTROLLED STUDY; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; PHARYNGITIS; PLASMA; PRIORITY JOURNAL; SINGLE DRUG DOSE; STREPTOCOCCUS GROUP A; TONSIL; TONSILLOPHARYNGITIS; TREATMENT RESPONSE; BIOLOGICAL MODEL; DRUG ADMINISTRATION; DRUG EFFECT; INTRAMUSCULAR DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; METABOLISM; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MONTE CARLO METHOD; PRESCHOOL CHILD; PROTEIN BINDING; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PYOGENES; TONSILLITIS;

ANTI-BACTERIAL AGENTS; CEFTRIAXONE; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; MONTE CARLO METHOD; PHARYNGITIS; PROTEIN BINDING; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES; TONSIL; TONSILLITIS;

EID: 29044441713     PISSN: 00314005     EISSN: 00314005     Source Type: Journal    
DOI: 10.1542/peds.2004-2294     Document Type: Article

References (25)

1. Pichichero ME, Casey JR, Mayes T, et al. Penicillin failure in streptococcal tonsillopharyngitis: causes and remedies. Pediatr Infect Dis J. 2000;19:917-923
2. Bisno AL, Gerber MA, Gwaltney JM Jr, et al. Practice guidelines for the diagnosis and management of group A streptococcal pharyngitis. Infectious Diseases Society of America. Clin Infect Dis. 2002;35:113-125
3. Pichichero ME. Group A streptococcal tonsillopharyngitis: cost-effective diagnosis and treatment. Ann Emerg Med. 1995;25:390-403
4. Pichichero ME. Controversies in the treatment of streptococcal pharyngitis. Am Fam Physician. 1990;42:1567-1576
5. Stillerman M. Comparison of oral cephalosporins with penicillin therapy for group A streptococcal pharyngitis. Pediatr Infect Dis. 1986;5:649-654
6. Pichichero ME, Green JL, Francis AB, et al. Recurrent group A streptococcal tonsillopharyngitis. Pediatr Infect Dis J. 1998;17:809-815
7. Brook I. Penicillin failure and copathogenicity in streptococcal pharyngotonsillitis. J Fam Pract. 1994;38:175-179
8. Brook I, Gober AE. Persistence of group A beta-hemolytic streptococci in toothbrushes and removable orthodontic appliances following treatment of pharyngotonsillitis. Arch Otolaryngol Head Neck Surg. 1998;124:993-995
9. Kim KS, Kaplan EL. Association of penicillin tolerance with failure to eradicate group A streptococci from patients with pharyngitis. J Pediatr. 1985;107:681-684
10. Bronze MS, Dale JB. The reemergence of serious group A streptococcal infections and acute rheumatic fever. Am J Med Sci. 1996;311:41-54
11. Stevens DL, Tanner MH, Winship J, et al. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N Engl J Med. 1989;321:1-7
12. Johnson DR, Wotton JT, Shet A, et al. A comparison of group A streptococci from invasive and uncomplicated infections: are virulent clones responsible for serious streptococcal infections? J Infect Dis. 2002;185:1586-1595
13. Pichichero ME, Hoeger W, Marsocci SM, et al. Variables influencing penicillin treatment outcome in streptococcal tonsillopharyngitis. Arch Pediatr Adolesc Med. 1999;153:565-570
14. el-Daher NT, Hijazi SS, Rawashdeh NM, et al. Immediate vs. delayed treatment of group A beta-hemolytic streptococcal pharyngitis with penicillin V. Pediatr Infect Dis J. 1991;10:126-130
15. ROCEPHIN (ceftriaxone sodium) for Injection Prescribing Information. Hoffman-La Roche; 1998. Available at: www.rocheusa.com/products/rocephin/pi.html
16. Cohen R, Navel M, Grunberg J, et al. One dose ceftriaxone vs. ten days of amoxicillin/clavulanate therapy for acute otitis media: clinical efficacy and change in nasopharyngeal flora. Pediatr Infect Dis J. 1999;18:403-409
17. Handsfield HH, Hook EW 3rd. Ceftriaxone for treatment of uncomplicated gonorrhea: routine use of a single 125-mg dose in a sexually transmitted disease clinic. Sex Transm Dis 1987;14:227-230
18. Kaplan EL, Johnson DR. Unexplained reduced microbiological efficacy of intramuscular benzathine penicillin G and of oral penicillin V in eradication of group a streptococci from children with acute pharyngitis. Pediatrics. 2001;108:1180-1186
19. Sheiner LB, Beal S, Rosenberg B, et al. Forecasting individual pharmacokinetics. Clin Pharmacol Ther. 1979;26:294-305
20. Sheiner LB, Beal SL. Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods. J Pharm Sci. 1982;71:1344-1348
21. Jelliffe R, Bayard D, Milman M, et al. Achieving target goals most precisely using nonparametric compartmental models and "multiple model" design of dosage regimens. Ther Drug Monit. 2000;22:346-353
22. D'Argenio DZ, Schumitzky A. A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Programs Biomed. 1979;9:115-134
23. Cellesi C, Chigiotti S, Zanchi A, et al. Susceptibility of macrolide and beta-lactam antibiotics of Streptococcus pyogenes strains isolated over a four-year period in central Italy. J Chemother. 1996;8:188-192
24. Yuk JH, Nightingale CH, Quintiliani R. Clinical pharmacokinetics of ceftriaxone. Clin Pharmacokinet. 1989;17:223-235
25. Leibovitz E, Piglansky L, Raiz S, Press J, Leiberman A, Dagan R. Bacteriologic and clinical efficacy of one day vs three day intramuscular ceftriaxone for treatment of nonresponsive acute otitis media in children. Pediatr Infect Dis J. 2000;19:1040-1045